Oral Administration of Water‐Soluble Curcumin Complex Prevents ARDS With the Potential for COVID‐19 Treatment

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Sinan Aktay, Yurixi Lopez‐Miranda, Jaakko Parkkinen, Krishnan Raghavendran, Madathilparambil V. Suresh
Natura: Artículo Open Access
Pubblicazione: Wiley 2025
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867017520579346432
author Sinan Aktay
Yurixi Lopez‐Miranda
Jaakko Parkkinen
Krishnan Raghavendran
Madathilparambil V. Suresh
author_facet Sinan Aktay
Yurixi Lopez‐Miranda
Jaakko Parkkinen
Krishnan Raghavendran
Madathilparambil V. Suresh
Sinan Aktay
Yurixi Lopez‐Miranda
Jaakko Parkkinen
Krishnan Raghavendran
Madathilparambil V. Suresh
collection Wiley Open Access
contents Oral Administration of Water‐Soluble Curcumin Complex Prevents ARDS With the Potential for COVID‐19 Treatment Sinan Aktay Yurixi Lopez‐Miranda Jaakko Parkkinen Krishnan Raghavendran Madathilparambil V. Suresh Phytotherapy Research ABSTRACTAcute respiratory distress syndrome (ARDS)—a form of severe lung injury—is often caused by conditions such as pneumonia, sepsis, and COVID‐19. COVID‐19, which enters cells through the angiotensin‐converting enzyme 2 (ACE2) receptor, has complications varying from mild infection to ARDS and death. Curcumin, a naturally occurring and safe anti‐inflammatory compound, has previously been formulated as a water‐soluble curcumin (CDC) to improve solubility and stability under physiologic conditions. CDC administration has been shown to improve cell survival and reduce inflammation, injury, and mortality in models of severe Klebsiella pneumoniae (KP) infection. This study aims to further evaluate the potential of CDC in treating COVID‐19, particularly complicated by ARDS. Lung samples from post‐mortem KP and COVID‐19 patients were evaluated for relevant markers with immunohistochemistry. Separately, mice inoculated with KP with or without CDC were evaluated for injury, inflammation, and expression of ACE2, STAT‐3, CXCL‐10, and IFN‐α. Mice treated with LPS with or without CDC were also evaluated similarly. Lung samples from KP patients had significantly higher ACE2 expression than normal lungs. Postmortem lung samples from COVID‐19 patients exhibited intense ACE2 staining compared to normal human lungs. Administration of CDC substantially reduced ACE2 expression at serum, gene, and protein levels after KP and LPS infection. Furthermore, CDC administration reduced the levels of STAT‐3, as well as the chemokine CXCL10, and interferon IFN‐α in KP‐infected mice. In vitro, data showed CDC administration reduced ACE2 and STAT3 expression in human lung epithelial cells following KP. Furthermore, administering CDC after LPS led to a significant decrease in injury, inflammation, and ACE2 levels. Based on the promising effects of CDC on these relevant markers, a proposal to use curcumin as a supportive therapy to treat ARDS and COVID‐19 to save lives is being considered. 10.1002/ptr.70046 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/ptr.70046
format Artículo Open Access
id wiley_oa_10_1002_ptr_70046
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2025
publisher Wiley
record_format wiley_oa
spellingShingle Oral Administration of Water‐Soluble Curcumin Complex Prevents ARDS With the Potential for COVID‐19 Treatment
Sinan Aktay
Yurixi Lopez‐Miranda
Jaakko Parkkinen
Krishnan Raghavendran
Madathilparambil V. Suresh
Phytotherapy Research
Oral Administration of Water‐Soluble Curcumin Complex Prevents ARDS With the Potential for COVID‐19 Treatment Sinan Aktay Yurixi Lopez‐Miranda Jaakko Parkkinen Krishnan Raghavendran Madathilparambil V. Suresh Phytotherapy Research ABSTRACTAcute respiratory distress syndrome (ARDS)—a form of severe lung injury—is often caused by conditions such as pneumonia, sepsis, and COVID‐19. COVID‐19, which enters cells through the angiotensin‐converting enzyme 2 (ACE2) receptor, has complications varying from mild infection to ARDS and death. Curcumin, a naturally occurring and safe anti‐inflammatory compound, has previously been formulated as a water‐soluble curcumin (CDC) to improve solubility and stability under physiologic conditions. CDC administration has been shown to improve cell survival and reduce inflammation, injury, and mortality in models of severe Klebsiella pneumoniae (KP) infection. This study aims to further evaluate the potential of CDC in treating COVID‐19, particularly complicated by ARDS. Lung samples from post‐mortem KP and COVID‐19 patients were evaluated for relevant markers with immunohistochemistry. Separately, mice inoculated with KP with or without CDC were evaluated for injury, inflammation, and expression of ACE2, STAT‐3, CXCL‐10, and IFN‐α. Mice treated with LPS with or without CDC were also evaluated similarly. Lung samples from KP patients had significantly higher ACE2 expression than normal lungs. Postmortem lung samples from COVID‐19 patients exhibited intense ACE2 staining compared to normal human lungs. Administration of CDC substantially reduced ACE2 expression at serum, gene, and protein levels after KP and LPS infection. Furthermore, CDC administration reduced the levels of STAT‐3, as well as the chemokine CXCL10, and interferon IFN‐α in KP‐infected mice. In vitro, data showed CDC administration reduced ACE2 and STAT3 expression in human lung epithelial cells following KP. Furthermore, administering CDC after LPS led to a significant decrease in injury, inflammation, and ACE2 levels. Based on the promising effects of CDC on these relevant markers, a proposal to use curcumin as a supportive therapy to treat ARDS and COVID‐19 to save lives is being considered. 10.1002/ptr.70046 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Oral Administration of Water‐Soluble Curcumin Complex Prevents ARDS With the Potential for COVID‐19 Treatment
topic Phytotherapy Research
url https://onlinelibrary.wiley.com/doi/10.1002/ptr.70046